Demonstrated strong improvements in financial performance and business momentum. Q3 revenue of $7.42 million increased 18.
7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues. Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.
3% to $7.1 million on a non-GAAP basis over Q2 2024. Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.
Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a regional Medicaid health plan, and a global leading pharma company. Made significant progress in transforming the pharma/medical device channel into a platform-based recurring revenue model by securing two new deals, including one with one of the top six global pharma companies. Dario remains on track to achieve operational cash flow breakeven run rate by the end of 2025.
Dario will host an investor conference call and webcast at 8:30 a.m. ET today.
Q3 2024 and Recent Highlights NEW YORK , Nov. 7, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO ) ("Dario" or the "Company"), a leader in the global digital health market, today announced its financial results for the third quarter of 2024, highlighting substantial improvements in financial performance and business momentum.
The Comp.
